Joanna Dewar

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study

Michael Byrne, Jennifer Davidson, Arthur W. Musk et al. · Journal of Clinical Oncology · 1999 · 335 citations

Impact of multidisciplinary team management in head and neck cancer patients

Peter Friedland, Biljana Božić, Joanna Dewar et al. · British Journal of Cancer · 2011 · 218 citations · Full text

Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer

James F. Bishop, Joanna Dewar, Guy C. Toner et al. · Journal of Clinical Oncology · 1999 · 211 citations

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

Evandro de Azambuja, Worta McCaskill‐Stevens, Prudence A. Francis et al. · Breast Cancer Research and Treatment · 2009 · 159 citations · Full text

Big 02-98, Breast Oncology, Oncology +8